{
  "ticker": "DVAX",
  "company_name": "Dynavax Technologies Corporation",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03934736",
      "title": "HEPLISAV-B\u00ae in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "End Stage Renal Disease on Hemodialysis (Diagnosis)",
      "start_date": "2019-04-22",
      "completion_date": "2021-09-15",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT04385524",
      "title": "Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection",
      "status": "WITHDRAWN",
      "phase": "NA",
      "condition": "Hepatitis B Virus",
      "start_date": "2020-06-01",
      "completion_date": "2021-02-28",
      "enrollment": 0,
      "sponsor": "University of Louisville"
    },
    {
      "nct_id": "NCT01195246",
      "title": "Safety and Immunogenicity of HEPLISAV\u2122 a Hepatitis B Virus Vaccine in Adults on Hemodialysis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "End Stage Renal Disease",
      "start_date": "2010-12",
      "completion_date": "2012-08",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT02266147",
      "title": "Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "B-cell Lymphoma",
      "start_date": "2014-10",
      "completion_date": "2017-04",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT00251394",
      "title": "Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Non-Hodgkin's Lymphoma",
      "start_date": "2004-07",
      "completion_date": "2009-07",
      "enrollment": 0,
      "sponsor": "Dana-Farber Cancer Institute"
    },
    {
      "nct_id": "NCT01023230",
      "title": "A Study to Assess DV-601 in Subjects With Chronic Hepatitis B",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hepatitis B, Chronic",
      "start_date": "2009-09",
      "completion_date": "2011-05",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT05506969",
      "title": "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018\u00ae Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Plague, Pneumonic, Plague, Vaccine-Preventable Diseases",
      "start_date": "2022-08-09",
      "completion_date": "2024-04-26",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT06569823",
      "title": "Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix\u00ae in Healthy Adults 50 Years of Age and Over",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Shingles, Herpes Zoster, Vaccine-Preventable Diseases",
      "start_date": "2024-06-17",
      "completion_date": "2031-11",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT07207408",
      "title": "Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis",
      "start_date": "2025-09-11",
      "completion_date": "2026-10-16",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    },
    {
      "nct_id": "NCT01282762",
      "title": "Long-Term Study on Safety and Immunogenicity of HEPLISAV\u2122 and Engerix-B\u00ae in Adults With Chronic Kidney Disease",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Chronic Kidney Disease",
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "enrollment": 0,
      "sponsor": "Dynavax Technologies Corporation"
    }
  ],
  "summary": {
    "total_trials": 30,
    "by_phase": {
      "PHASE1": 11,
      "NA": 1,
      "PHASE3": 6,
      "PHASE1, PHASE2": 3,
      "PHASE2": 7,
      "": 2
    },
    "by_status": {
      "COMPLETED": 21,
      "WITHDRAWN": 1,
      "TERMINATED": 5,
      "RECRUITING": 2,
      "UNKNOWN": 1
    },
    "active_trials": 2,
    "completed_trials": 21,
    "conditions": [
      "Advanced Non Small Cell Lung Cancer",
      "B-cell Lymphoma",
      "Chronic Hepatitis C",
      "Chronic Kidney Disease",
      "Colorectal Neoplasms",
      "End Stage Renal Disease",
      "End Stage Renal Disease on Hemodialysis (Diagnosis)",
      "HIV Infection, Hepatitis B",
      "HIV Infections",
      "Healthy",
      "Hepatitis B",
      "Hepatitis B Virus",
      "Hepatitis B, Chronic",
      "Metastatic Melanoma, Head Neck Cancer",
      "Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8",
      "Non-Hodgkin's Lymphoma",
      "Plague, Pneumonic, Plague, Vaccine-Preventable Diseases",
      "Pregnant",
      "Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis",
      "Rhinitis, Allergic, Seasonal",
      "Shingles, Herpes Zoster, Vaccine-Preventable Diseases"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:05.389024",
    "search_query": "Dynavax Technologies Corporation",
    "url": "https://clinicaltrials.gov/search?term=Dynavax+Technologies+Corporation"
  }
}